Completed OBSERVATIONAL NCT00969319

Effekt-2 - Efficacy and Safety of Long-term Treatment With KOGENATE® FS in Latin America

Sponsor: Bayer

Conditions Blood Coagulation Disorders Hemophilia A

Interventions Recombinant Factor VIII (Kogenate FS, BAY14-2222)

Updated 10 times since 2017 Last updated: Jan 16, 2015 Started: Sep 30, 2009 Primary completion: Feb 28, 2013 Completion: Feb 28, 2014

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A observational or N/A phase clinical study on Blood Coagulation Disorders and Hemophilia A, this trial is completed. The trial is conducted by Bayer and has accumulated 10 data snapshots since 2009. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

10 versions recorded

Sep 2025 — Present [monthly]

Completed
Sep 2024 — Sep 2025 [monthly]

Completed
Jul 2024 — Sep 2024 [monthly]

Completed
Jan 2021 — Jul 2024 [monthly]

Completed
Feb 2020 — Jan 2021 [monthly]

Completed

▶ Show 5 earlier versions

Jun 2018 — Feb 2020 [monthly]

Completed
May 2018 — Jun 2018 [monthly]

Completed
Apr 2018 — May 2018 [monthly]

Completed

Phase: NA → None
Aug 2017 — Apr 2018 [monthly]

Completed NA
Jan 2017 — Aug 2017 [monthly]

Completed NA

First recorded

Sep 2009

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Bayer

Data source: Bayer

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Many Locations, Mexico
• Many Locations, Venezuela